Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma - subgroup analysis of the PEVOsq basket trial

被引：0
|
作者：
Le Tourneau, C. [1 ]
Ghiringhelli, F. [2 ]
Saada, E. B. [3 ]
Chaltiel, R. [4 ]
Vansteene, D. [5 ]
Durando, X. [6 ]
You, B. [7 ]
Borel, C. [8 ]
Bigot, F. [9 ]
Abdeddaim, C. [10 ]
Marret, G. [11 ]
Jeannot, E. [12 ]
Rocco, E. Guerini [13 ]
Frige, G. [14 ]
Servant, N. [15 ]
Dupain, C. [16 ]
Kamal, M. [16 ]
Legrand, F. [17 ]
Jimenez, M. [17 ]
Filleron, T. [18 ]
机构：
[1] Inst Curie, Dept Drug Dev & Innovat D3i, Paris, France
[2] Ctr Georges Francois Leclerc Dijon, Med Oncol, Dijon, France
[3] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France
[4] CHU Reims, Hop Robert Debre, Reims, France
[5] ICO Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France
[6] Ctr Jean PERRIN, F-63000 Clermont Ferrand, France
[7] HCL, Ctr Hosp Lyon Sud, Oncol Dept, Pierre Benite, France
[8] Ctr Lutte Canc, Ctr Paul Strauss, Med Oncol Dept, Strasbourg, France
[9] ICO Inst Cancerol Ouest, Dept Med Oncol, Site Paul Papin, Angers, France
[10] Ctr Oscar Lambret, Dept Med Oncol, Lille, France
[11] Inst Curie, Dept Drug Dev & Innovat, Paris, France
[12] Inst Curie, Pathol, Paris, France
[13] IEO Ist Europeo Oncol IRCCS, Dept Med Oncol, Milan, Italy
[14] IEO Ist Europeo Oncol, Expt Oncol, Milan, Italy
[15] Inst Curie, Dept Med Oncol, Paris, France
[16] Inst Curie, Drug Dev & Innovat Dept, Paris, France
[17] UNICANCER, R&D Dept, Paris, France
[18] IUCT Oncopole, Inst Claudius Regaud, Haute Garonne, Toulouse, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
923P
引用
收藏
页码：S583 / S583
页数：1
相关论文
共 50 条
  • [31] Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
    Massarelli, E.
    Lin, H.
    Ginsberg, L. E.
    Tran, H. T.
    Lee, J. J.
    Canales, J. R.
    Williams, M. D.
    Blumenschein, G. R., Jr.
    Lu, C.
    Heymach, J. V.
    Kies, M. S.
    Papadimitrakopoulou, V.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1476 - 1480
  • [32] POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
    Forster, M. D.
    Mason, J.
    Moleron, R.
    Sacco, J. J.
    Beasley, M.
    Ferreira, M. Reis
    Srinivasan, D.
    Yip, K.
    Stewart, G.
    Chiu, K.
    Ward, A.
    Metcalf, R.
    Adedoyin, T.
    Begum, R.
    Chiwewe, M.
    Poole, K.
    Spanswick, V.
    Pathak, Y.
    Counsell, N.
    Rashid, M. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S623 - S624
  • [33] A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
    Swiecicki, P. L.
    Durm, G.
    Bellile, E.
    Brummel, C.
    Pang, M.
    Bhangale, A.
    Brenner, J. C.
    Worden, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1178 - 1179
  • [34] A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
    Swiecicki, Paul L.
    Durm, Greg
    Bellile, Emily
    Bhangale, Apurva
    Brenner, J. Chad
    Worden, Francis P.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1550 - 1558
  • [35] A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
    Paul L. Swiecicki
    Greg Durm
    Emily Bellile
    Apurva Bhangale
    J. Chad Brenner
    Francis P. Worden
    Investigational New Drugs, 2020, 38 : 1550 - 1558
  • [36] Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
    Shin, DM
    Glisson, BS
    Khuri, FR
    Ginsberg, L
    Papadimitrakopoulou, V
    Lee, JJ
    Lawhorn, K
    Gillenwater, AM
    Ang, KK
    Clayman, GL
    Callender, DL
    Hong, WK
    Lippman, SM
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1325 - 1330
  • [37] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, H-F.
    Hong, R-L.
    ANNALS OF ONCOLOGY, 2018, 29 : 379 - 379
  • [38] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, Hsiang-Fong
    Huang, Huai-Cheng
    Liao, Bin-Chi
    Hong, Ruey-Long
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [39] Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
    Fayette, J.
    Thomas, G.
    Daste, A.
    Rotarski, M.
    Castelo, B.
    Rullan, A.
    Levine, A.
    Philipson, R. S.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S615 - S616
  • [40] PHASE-II TRIAL OF PIROXANTRONE IN PATIENTS WITH RECURRENT AND METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A SOUTHWEST-ONCOLOGY-GROUP TRIAL
    TAYLOR, SA
    BENEDETTI, J
    SCHULLER, D
    RICHMAN, SP
    BROUN, GO
    HANTEL, A
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) : 227 - 229
12345